Has Saradha Chexal, MD received payments from drug or device companies?

Yes. Drug and device makers reported $35,772 in general payments to Saradha Chexal, MD across 179 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Saradha Chexal, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Saradha Chexal, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Saradha Chexal, MD

Ophthalmology · Austin, TXNPI 1013258730

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $25,641 of the $35,772 with a category attached, or 71.7%. AbbVie accounts for 65.5% of it on its own, with 19 other manufacturers making up the rest. Among ophthalmology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$35,772in general payments, 2019–2025

Across 179 payments — averaging $199.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$23K
Genentech USA, Inc.$5K
Ocular Therapeutix, Inc.$3K
Genentech, Inc.$2K
Novartis$571
Alcon Research LLC$518
plus $2K from 14 others

$1,724,582in research payments, 2019–2025

Across 119 payments — averaging $14,492 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Ocular Therapeutix, Inc.$618K
Genentech, Inc.$549K
Bayer$454K
Novartis$103K

What the payments were for

Consulting fees$25,64172%
Travel & lodging$4,46912%
Food & beverage$5,62316%
Gifts$390%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	64	$23,419
Genentech USA, Inc.	25	$4,605
Ocular Therapeutix, Inc.	12	$2,890
Genentech, Inc.	13	$2,236
Novartis	13	$571
Alcon Research LLC	1	$518
Regeneron Healthcare Solutions, Inc.	18	$489
Astellas Pharma US Inc	10	$276
Eyepoint US, Inc.	3	$139
Alimera Sciences, Inc.	3	$121
Apellis Pharmaceuticals, Inc.	5	$119
Regeneron	2	$85
Thrombogenics, Inc.	1	$66
Oyster Point Pharma, Inc.	1	$63
Carl Zeiss Meditec AG	2	$39
Biogen	2	$38
Alcon	1	$33
Astellas Pharma Global Development	1	$30
Bausch & Lomb, A Division Of Bausch Health US, LLC	1	$18
Coherus Oncology, Inc.	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,772 in reported general payments places this provider in the 90th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas →

Medicare billing

Part B allowed, 2024

$1,677,733

Medicare patients

613

Services billed

20,072

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Prednisolone Acetate	80	$2,850
Brimonidine Tartrate	14	$841
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat	21	$229
Ofloxacin	23	$221
Latanoprost	25	$220
Ciprofloxacin Hcl	21	$212

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Austin

Chirag JhaveriAustin$240K
Sheila BarbarinoAustin$232K
Aaron RollerAustin$202K
Philip StoreyAustin$161K
Robert WongAustin$113K
Farhan IrshadAustin$111K
Edward WoodAustin$110K
Ryan YoungAustin$105K
Steven DellAustin$94K
Shelley GhafooriAustin$73K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →